Joint Meeting of the National Center for Advancing Translational Sciences Advisory Council (6th Meeting) and Cures Acceleration Network Review Board (7th Meeting)

May 16, 2014
8:30 a.m. - 5:00 p.m.
Building 31C, 6th Floor, Conference Room 10
Bethesda, Maryland 20892

FUTURE COUNCIL and CAN BOARD MEETINGS

<table>
<thead>
<tr>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>September 19</td>
<td>January 15-16</td>
</tr>
<tr>
<td></td>
<td>May 21-22</td>
</tr>
<tr>
<td></td>
<td>September 24-25</td>
</tr>
<tr>
<td>CAN Board only (by phone)</td>
<td>December 12</td>
</tr>
<tr>
<td>December 12</td>
<td>December 11</td>
</tr>
</tbody>
</table>

Agenda – OPEN SESSION

Open Session of the meeting will be webcast. To view, please go to: http://videocast.nih.gov/summary.asp?live=14070

8:30 - 8:50 a.m. CALL TO ORDER, OPEN SESSION
Christopher P. Austin, M.D. Freda Lewis-Hall, M.D.
Director, NCATS Chief Medical Officer, Pfizer
Chairperson - Advisory Council Chairperson - CAN Board

8:50 - 9:00 a.m. Approval of Minutes from January 2014 Joint Meeting

Confirmation of Dates for Future NCATS Advisory Council/CAN Review Board Meetings
Danilo A. Tagle, Ph.D., Executive Secretary, NCATS Advisory Council

9:00 - 10:00 a.m. NCATS DIRECTOR’S REPORT
Christopher P. Austin, M.D., Director, NCATS
Discussion
10:00 - 10:30 a.m.  BREAK

10:30 a.m. - 12:30 p.m.  NCATS Advisory Council Working Group on the IOM Report: The CTSA Program at NIH

Mary L. (Nora) Disis, M.D., Professor, Department of Medicine
University of Washington School of Medicine

Scott J. Weir, Pharm.D., Ph.D., Director, Institute for Advancing Medical Innovation
University of Kansas Cancer Center

Ronald J. Bartek, President/Director/Co-Founder
FARA/Friedreich’s Ataxia Research Alliance

Discussion

12:30 - 1:30 p.m.  LUNCH

1:30 - 2:15 p.m.  CAN Review Board
   • Process for Transition to Second Phase of Organs-on-Chips program
      Danilo A. Tagle, Ph.D., NCATS
      Discussion

   • Prioritization of Future CAN Focus Areas
      Freda Lewis-Hall, M.D., Chief Medical Officer, Pfizer
      Discussion

2:15 - 2:45 p.m.  REPORT FROM COUNCIL SUBCOMMITTEES
   • Patient engagement
      Margaret A. Anderson, M.A. and Myrl Weinberg, M.A.
   • Partnerships with pharmaceutical and biotechnology companies and venture capital firms
      Freda Lewis-Hall, M.D. and Ankit A. Mahadevia, M.D., M.B.A.
   • Medical technologies (devices and diagnostics)
      Frank L. Douglas, Ph.D., M.D. and Paul G. Yock, M.D.

Discussion
2:45 - 3:15 p.m.  CONCEPT CLEARANCE
  • Proposed CTSA initiatives

   Petra Kaufmann, M.D., M.Sc., Director, Division of Clinical
   Innovation, NCATS

3:15 p.m.  ADJOURN, OPEN SESSION

3:30 - 5:00 p.m.  CLOSED SESSION

This portion of the meeting is closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.
Code and Section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2).

Review of Conflict of Interest, Confidentiality and Council
Procedures

   Danilo A. Tagle, Ph.D., Executive Secretary, NCATS Advisory Council

Council Consideration of Pending Applications

   Danilo A. Tagle, Ph.D., Executive Secretary, NCATS Advisory Council